Click the icon to add a specified price to your Dashboard list. This makes it easy to keep track on the prices that matter most to you.
Teijin Limited, Teijin Regenet Co., Ltd., and Shinshu University Hospital announced that they have entered into a joint research agreement regarding manufacturing technologies for cell and gene therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. The collaboration aims to advance manufacturing technologies and strengthen Japan's manufacturing infrastructure for cell and gene therapies, thereby contributing to the broader availability of these innovative treatments
Cell and gene therapies, including CAR-T cell therapies, are expected to become increasingly important treatment options for cancer and other intractable diseases. In Japan, however, expanding the availability of specialized manufacturing personnel and manufacturing facilities remain significant challenges, underscoring the need for a more robust and sustainable supply framework.
Under the joint research agreement, Shinshu University Hospital's expertise in CAR-T cell therapy research, development and clinical application will be combined with Teijin Regenet's manufacturing and quality-management know-how cultivated through its contract development and manufacturing organization (CDMO) business for regenerative medicine products. The partners will work together to enhance manufacturing technologies and strengthen the manufacturing base for cell and gene therapies.
The collaboration will also utilize the Cell Processing Center (CPC) at Shinshu University Hospital to explore future manufacturing automation and efficiency improvements. In addition, the partners will work to accumulate practical knowledge related to quality testing technologies and quality-control methodologies.
Going forward, Teijin, Teijin Regenet and Shinshu University Hospital will leverage the outcomes of this joint research to contribute to the advancement of cell and gene therapies in Japan and help create an environment in which patients can more readily access the treatments they need.
About the Teijin Group
Teijin is a global group that co-creates value with Customer-Driven businesses across the Apparel & Industries, Healthcare & Life Solutions, Electronics & Energy, and Specialty Materials domains. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 125 companies employing approximately 15,700 people. Teijin is committed to its Purpose: Pioneering solutions together for a healthy planet. Teijin works together with employees and external partners to achieve its Long-Term Vision: To be a company that supports the society of the future. Teijin posted consolidated revenue of JPY 873.2 billion and total assets of JPY 920.1 billion in the fiscal year ending March 31, 2026.
About Teijin Regenet
Teijin Regenet Co., Ltd.,established in 2023, is a Teijin Group company dedicated exclusively to providing contract development and manufacturing services for Cell & Gene Therapy and Regenerative Medicines (CGT&RM). By leveraging its industrialization platform for CGT&RM products and its manufacturing facilities in Kashiwa, Chiba Prefecture and Iwakuni, Yamaguchi Prefecture, the company provides one-stop CDMO services ranging from process development to commercial manufacturing.
About Shinshu University Hospital
Shinshu University Hospital is a leading academic medical institution located in Matsumoto, Nagano Prefecture, Japan. Through its advanced clinical and research activities, including those conducted at its Cell Processing Center (CPC), the hospital contributes to the development of innovative medical technologies and therapies, including regenerative medicine and cell-based therapies.
Note: This story has not been edited by The Polymerupdate Editorial team and is auto-generated from a syndicated feed.
